SCG announces presentation of clinical results of SCG142 in patients with HPV-related carcinoma at ESMO 2025
SINGAPORE, Oct. 18, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing next-generation immunotherapies for infectious diseases and their associated cancers, announced the presentation of first-in-human clinical data for SCG142 in an investigator-initiated Phase I trial (NCT06544720) in patients with recurrent or metastatic HPV-associated carcinomas. The poster will be presented at the European Society...
Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) and...
AMT-116 is a potential first-in-class CD44v9-directed Topoisomerase I inhibitor-based ADC AMT-116 demonstrated a favorable safety profile, with manageable hematologic and Gastrointestinal toxicities Promising efficacies were observed in patients with heavily pretreated EGFR Wild-type NSCLC and other advanced solid tumors without CD44v9 pre-selection SHANGHAI, Oct. 17, 2025 /PRNewswire/ -- Multitude Therapeutics, Inc., a clinical-stage company focused on...
NYSE Content Advisory: Pre-Market Update + Automakers await 5-year tariff relief extension
NEW YORK, Oct. 17, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-Market Update + Automakers await 5-year tariff relief extension...
Kelun-Biotech’s Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC
CHENGDU, China, Oct. 17, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate (ADC) trastuzumab botidotin (also known as A166) was approved for marketing by the National Medical Products Administration (NMPA) for the treatment of adult patients with unresectable or metastatic HER2-positive breast...
One Heung Kong released the White Paper on Global Sustainable and Healthy Living Environments jointly with other institutions
GUANGZHOU, China, Oct. 17, 2025 /PRNewswire/ -- On October 14, the 2025 Global Engineering Conference and the first World Green Design Conference opened in Shanghai, China, drawing together over 250 former senior UN officials, academicians from different countries, and representatives from Fortune 500 companies. At the event, the White Paper on Global Sustainable and Healthy Living Environments (the Global Healthy...
One Heung Kong Leads the Way! New Global Benchmark for Healthy Living Announced
GUANGZHOU, China, Oct. 17, 2025 /PRNewswire/ -- On October 14, the 2025 Global Engineering Conference and the first World Green Design Conference opened in Shanghai, China, drawing together over 250 former senior UN officials, academicians from different countries, and representatives from Fortune 500 companies. At the event, the White Paper on Global Sustainable and Healthy Living Environments (the Global...
HMI Medical Signs MOA With Ibraco Berhad To Acquire Land For The Establishment Of Its Third Hospital In Malaysia
The new tertiary hospital will be located within the NorthBank Township in Kuching, Sarawak and is targeted to launch in 2029 SINGAPORE, Oct. 17, 2025 /PRNewswire/ -- Health Mangement International Pte Ltd ("HMI Medical") has signed a Memorandum of Agreement ("MoA") with KLSE listed and Sarawak-based property and infrastructure developer, Ibraco Berhad, ("Ibraco")...
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences
New business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate access to innovative medicines for patients worldwide Intention to pursue a Hong Kong initial public offering (IPO) to expand access to global capital and innovation through dual listing on NASDAQ and Hong Kong Stock Exchange (HKEX) Name...
FDA approves expanded pediatric indications for YUFLYMA® (adalimumab-aaty) and unbranded adalimumab-aaty in the United States
YUFLYMA® (adalimumab-aaty), and its unbranded version, are now approved for two additional pediatric indications – adolescent hidradenitis suppurativa (HS) and pediatric uveitis (UV), in the U.S., Pediatric UV is a rare eye inflammation in children, representing 5–10% of all uveitis cases in the U.S., while HS affects approximately 1–4% of the...
Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot
Illumina's up-and-coming constellation innovation delivers accuracy, speed, and ease of use in trial by GeneDx Constellation outperformed orthogonal methods in identifying select difficult-to-map variants SAN DIEGO, Oct. 17, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced that GeneDx, a leader in genetic testing for rare diseases, is piloting Illumina's emerging constellation mapped read technology,...
